Successful <i>Helicobacter pylori</i> eradication therapy improves symptoms of chronic constipation

Background and Aims:Anti-Helicobacter pylori therapy may lead to the growth of pathogenic or antibiotic-resistant bacteria in the gut. The study aimed to investigate the shortterm and long-term impacts of H. pylori eradication with reverse hybrid therapy on the components and macrolide resistance of the gut microbiota. Methods: Helicobacter pylori-related gastritis patients were administered a 14-day reverse hybrid therapy. Fecal samples were collected before treatment and at the end of week 2, week 8, and week 48. The V3-V4 region of the bacterial 16S rRNA gene in fecal specimens was amplified by polymerase chain reaction and sequenced on Illumina MiSeq platform. Additionally, amplification of erm(B) gene (encoding erythromycin resistance methylase) was performed. Results: Reverse hybrid therapy resulted in decreased relative abundances of Firmicutes (from 62.0% to 30.7%; P < 0.001) and Actinobacteria (from 3.4% to 0.6%; 0.032) at the end of therapy. In contrast, the relative abundance of Proteobacteria increased from 10.2% to 49.1% (0.002). These microbiota alterations did not persist but returned to the initial levels at week 8 and week 48. The amount of erm(B) gene in fecal specimens was comparable with the pretreatment level at week 2 but increased at week 8 (0.025) and then returned to the pretreatment level by week 48. Conclusions: Helicobacter pylori eradication with reverse hybrid therapy can lead to short-term gut dysbiosis. The amount of erm(B) gene in the stool increased transiently after treatment and returned to the pretreatment level at 1-year post-treatment.

show abstract

“…Murata et al . revealed that anti‐ H. pylori therapy improved symptoms of chronic constipation . On the other hand, Imase et al .…”

Section: Discussionmentioning

confidence: 99%

Short‐term and long‐term impacts of Helicobacter pylori eradication with reverse hybrid therapy on the gut microbiota

Hsu

Pan

Kao

et al. 2019

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…In this study, we also found that the richness and diversity of gastric species were lower in H. pylori -positive patients than in H. pylori -negative patients according to alpha diversity indexes. In recent years, it has been reported that there is a significant difference in the gastric mucosal microbiota between H. pylori -positive and H. pylori -negative subjects ( Murata et al., 2018 ; Park et al., 2019 ; Miftahussurur et al., 2020 ), and that H. pylori infection has also been found to have a significant impact on the structure of the gastric microbiota in animal models ( He et al., 2016 ; Kienesberger et al., 2016 ; Miao et al., 2020 ). Among individuals infected with H. pylori , the dominant bacterial categories in the stomach are mainly Proteobacteria , Firmicutes , and Actinobacteria .…”

Section: Discussionmentioning

confidence: 99%

Refractory Helicobacter pylori infection and the gastric microbiota

Wang²,

Xie³

2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

BackgroundCuring refractory Helicobacter pylori infection is difficult. In addition, there is currently no research on the gastric microbiota of refractory H. pylori infection.MethodsWe designed a clinical retrospective study involving 32 subjects divided into three groups: 1. nAGHp.a, treatment-naïve patients with H. pylori infection; 2. nAGHp.b, H. pylori-negative patients; and 3. EFHp.a, patients with refractory H. pylori infection. Gastric mucosal samples from the biobank of our research center were collected for 16S rRNA sequencing analysis and bacterial functions were predicted via PICRUSt.ResultsThere were significant differences between the H. pylori- positive group and the H. pylori-negative group in species diversity, gastric microbiota structure, and bacterial function. The beneficial Lactobacillus in the H. pylori-positive group were significantly enriched compared with those in the refractory H. pylori infection group. The bacterial interaction network diagram suggested that the microbiota interactions in the refractory H. pylori infection group decreased. The gastric microbiota of the refractory H. pylori infection group was enriched in the pathways of metabolism and infectious diseases (energy metabolism, bacterial secretion system, glutathione metabolism, protein folding and associated processing, sulphur metabolism, membrane and intracellular structural molecules, lipopolysaccharide biosynthesis, ubiquinone and other terpenoid-quinone biosynthesis, inorganic ion transport and metabolism, and metabolism of cofactors and vitamins) when compared with the H. pylori-positive group without treatment based on PICRUSt analysis.ConclusionSignificant alterations occurred in the gastric microbiota when eradication of H. pylori failed multiple times. A history of eradication of multiple H. pylori infections leads to an imbalance in the gastric mucosal microbiota to a certain extent, which was mainly reflected in the inhibition of the growth of beneficial Lactobacillus in the stomach. Patients with refractory H. pylori infection may be at a higher risk of developing gastric cancer than other H. pylori-positive patients.

show abstract

“…Until now, only a few studies have shown less frequent diarrhea after therapy, but it has been combined with probiotic use [ 26 , 27 ]. Additionally, eradication therapy might improve constipation symptoms, as shown by Murata et al [ 28 ]. In the case of constipation and diarrhea, we can assume that less antibiotics may have a less negative influence on gut microbiota, which can lead to less disturbance in bowel movement.…”

Section: Discussionmentioning

confidence: 99%

Impact of Different Helicobacter pylori Eradication Therapies on Gastrointestinal Symptoms

et al. 2021

View full text Add to dashboard Cite

Background and Objectives: Helicobacter pylori (H. pylori) infection impairs quality of life. However, whether eradication therapy ameliorates gastrointestinal symptoms remains questionable. The main objective of this study was to evaluate the influence of H. pylori eradication therapy on gastrointestinal symptoms. Materials and Methods: A total of 140 patients, 59 women and 81 men, with a mean age of 61 and suffering from H. pylori infection in the University Hospital of Split, Croatia, were enrolled in the study. Patients were randomly assigned to either concomitant or hybrid therapies. The Gastrointestinal Symptom Rating Scale (GSRS) questionnaire was completed by patients prior to and after the eradication therapy. Results: In both groups, the total GSRS score improved significantly after therapy. In the concomitant group, the abdominal pain score, reflux symptoms score and indigestion score decreased significantly after therapy. In the group with hybrid therapy, all five groups of symptoms (abdominal pain, reflux symptoms, indigestion, diarrhea and constipation) significantly decreased after therapy. Patients with adverse events had significantly higher total GSRS scores after eradication therapy. Conclusions: H. pylori eradication therapy could alleviate gastrointestinal symptoms regardless of the treatment used, but the favorable effect seemed to be more pronounced after hybrid therapy.

show abstract

Successful Helicobacter pylori eradication therapy improves symptoms of chronic constipation

Cited by 13 publications

References 46 publications

Short‐term and long‐term impacts of Helicobacter pylori eradication with reverse hybrid therapy on the gut microbiota

Short‐term and long‐term impacts of Helicobacter pylori eradication with reverse hybrid therapy on the gut microbiota

Refractory Helicobacter pylori infection and the gastric microbiota

Impact of Different Helicobacter pylori Eradication Therapies on Gastrointestinal Symptoms

Contact Info

Product

Resources

About